Clinical significance of SARS‐CoV‐2‐specific IgG detection with a rapid antibody kit for COVID‐19 patients

Chong, Yong Pil; Ikematsu, Hideyuki; Tani, Naoki; Arimizu, Yoko; Watanabe, Hironosuke; Fukamachi, Yukako; Yonekawa, Akiko; Iwasaka, Sho; Nishida, Ruriko; Eriguchi, Yoshihiro; Miyake, Noriko; Shimoda, Shinji; Nagasaki, Yoji; Shimono, Nobuyuki; Akashi, Koichi

doi:10.1111/irv.12802

Cited by 8 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Guo et al reported that the positive rates of IgM antibodies and IgG antibodies in SARS‐CoV‐2‐infected patients increased significantly after 7–14 days of symptoms 8 . Another study reported that the IgG detection rates reached 100.0% in samples collected on day 13 or later using an immunochromatographic assay kit 9 . Considering the uncertainty of the time patients can recall the symptoms, this study used the number of days of admission as the basis for grouping.…”

Section: Discussionmentioning

confidence: 99%

“…8 Another study reported that the IgG detection rates reached 100.0% in samples collected on day 13 or later using an immunochromatographic assay kit. 9 Considering the uncertainty of the time patients can recall the symptoms, this study used the number of days of admission as the basis for grouping. The results showed that the positive rates of IgM and IgG antibodies 1-3 days, 4-6 days, 7-9 days and more than 9 days after admission (see Figure 3) were 50%, 70%, 92.5% and 97.5%, respectively, suggesting that the antibody positivity rate increased rapidly during the early stages of infection, and antibody detection can be used as an indicator for SARS-CoV-2 infection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Development of a SARS‐CoV‐2 rapid antibody detection kit and study on dynamic changes in antibodies in infected patients

Wang

et al. 2021

Clinical Respiratory J

View full text Add to dashboard Cite

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread rapidly to 185 regions and countries around the world with more than 2.8 million confirmed infections and 203,044 deaths. Respiratory diseases caused by SARS‐CoV‐2 are serious threats to human health. Objectives To develop a rapid detection kit for new coronavirus antibodies and use it to study the dynamic changes in antibodies in clinically confirmed SARS‐CoV‐2‐infected patients. Methods The SARS‐CoV‐2 IgM/IgG antibody test kit (colloidal gold method) was developed. Serum SARS‐CoV‐2 IgM and IgG antibodies were tested in SARS‐CoV‐2‐ and non‐SARS‐CoV‐2‐infected persons, respectively. Results and conclusion The sensitivities of the SARS‐CoV‐2 IgM/IgG antibody test kit (colloidal gold method) were 50%, 70%, 92.5% and 97.5% after 1–3 days, 4–6 days, 7–9 days and >9 days of admission, respectively, and the specificities of the IgM, IgG and IgM + IgG antibodies were all 100%. Using the SARS‐CoV‐2 IgM/IgG antibody test kit (colloidal gold method), the positive rates of SARS‐CoV‐2 IgM and IgG antibodies increased from 50% to 92.5% after 1–3 days, 4–6 days and 7–9 days of admission, which showed an increasing trend. The titers of the SARS‐CoV‐2 IgM and IgG antibodies in the positive specimens increased with the length of admission.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Development of a SARS‐CoV‐2 rapid antibody detection kit and study on dynamic changes in antibodies in infected patients

Wang

et al. 2021

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“… Antigen tests : analysis of the viral proteins (membrane-bound spike proteins or the nucleocapsid proteins) using techniques such as colorimetric, field-effect transistor (FET), enzyme-linked immunosorbent assay (ELISA), and mass spectrometry (MS). Serological tests : analysis of the antibodies (Immunoglobulin M (IgM) and Immunoglobulin G (IgG)) against the virus [ 188 – 190 ]. The study of patient's antibodies can be achieved using methods such as electrical (EC) biosensors, localized surface plasmon resonance (LSPR), surface-enhanced Raman scattering (SERS), quartz crystal microbalance (QCM), fluorescence-based biosensor, colorimetric biosensor, gold immunochromatography, ELISA, chemiluminescence immunoassay, and piezoelectric microcantilever sensors (PEMS).…”

Section: Introductionmentioning

confidence: 99%

Nanobiotechnology as a platform for the diagnosis of COVID-19: a review

Abdelhamid

Badr

2021

Nanotechnol. Environ. Eng.

View full text Add to dashboard Cite

A sensitive method for diagnosing coronavirus disease 2019 (COVID-19) is highly required to fight the current and future global health threats due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2). However, most of the current methods exhibited high false-negative rates, resulting in patient misdiagnosis and impeding early treatment. Nanoparticles show promising performance and great potential to serve as a platform for diagnosing viral infection in a short time and with high sensitivity. This review highlighted the potential of nanoparticles as platforms for the diagnosis of COVID-19. Nanoparticles such as gold nanoparticles, magnetic nanoparticles, and graphene (G) were applied to detect SARS-CoV 2. They have been used for molecular-based diagnosis methods and serological methods. Nanoparticles improved specificity and shorten the time required for the diagnosis. They may be implemented into small devices that facilitate the self-diagnosis at home or in places such as airports and shops. Nanoparticles-based methods can be used for the analysis of virus-contaminated samples from a patient, surface, and air. The advantages and challenges were discussed to introduce useful information for designing a sensitive, fast, and low-cost diagnostic method. This review aims to present a helpful survey for the lesson learned from handling this outbreak to prepare ourself for future pandemic.

show abstract

“…6,7 However, studies clearly demonstrated that the presence of anti-SARS-CoV-2 IgG does not indicate viral clearence. 1,8 Nevertheless, a report by Long et al 4 verified that moderate and severe COVID-19 patients present a distinct IgM and IgG production course. Severe patients develop IgG seroconversion earlier in relation to moderate patients.…”

mentioning

confidence: 99%

“…2 Reports have detected IgG production between 5 and 9 days after infection. 1,3,4 Nevertheless, patients with some comorbidities, such as HIV, can present a delayed immune response against SARS-CoV-2, with detectable anti-SARS-CoV-2 immunoglobulin only after 60 days after the infection. 5 Anti-SARS-CoV-2 IgG may block and neutralize SARS-CoV-2 and prevent COVID-19 development.…”

mentioning

confidence: 99%

What is the long‐term clinical significance of anti‐SARS‐CoV‐2‐specific IgG?

Alberca

2020

Influenza Resp Viruses

View full text Add to dashboard Cite

We read with great interest the article "Clinical significance of SARS-CoV-2-specific IgG detection with a rapid antibody kit for COVID-19 patients" by Chong et al 1 The manuscript discusses the possible implications of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-specific Immunoglobulin G (IgG) production and the concomitant positivity in SARS-CoV-2 detection by polymerase chain reaction (PCR) in asymptomatic and symptomatic patients. This study raises some interesting questions, and we would like to humbly state a few points about the possible long-term implications of these results. SARS-CoV-2-infected patients may or may not have symptoms.Individuals that present symptoms can range from mild to severe respiratory and systemic disease, named coronavirus disease-2019Patients infected with SARS-CoV-2 can generate high titters of SARS-CoV-2-specific antibody isotypes, such as IgA, IgG, and

show abstract

Clinical significance of SARS‐CoV‐2‐specific IgG detection with a rapid antibody kit for COVID‐19 patients

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 8 publications

References 14 publications

Development of a SARS‐CoV‐2 rapid antibody detection kit and study on dynamic changes in antibodies in infected patients

Development of a SARS‐CoV‐2 rapid antibody detection kit and study on dynamic changes in antibodies in infected patients

Nanobiotechnology as a platform for the diagnosis of COVID-19: a review

What is the long‐term clinical significance of anti‐SARS‐CoV‐2‐specific IgG?

Contact Info

Product

Resources

About